{"id":565826,"date":"2026-09-28T00:30:00","date_gmt":"2026-09-27T22:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=565826"},"modified":"2026-09-26T23:09:45","modified_gmt":"2026-09-26T21:09:45","slug":"the-sglt-2-inhibitor-dapagliflozin-as-an-add-on-to-ras-blockade","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/the-sglt-2-inhibitor-dapagliflozin-as-an-add-on-to-ras-blockade\/","title":{"rendered":"The SGLT-2 inhibitor dapagliflozin as an add-on to RAS blockade"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>The broad spectrum of therapeutic effects of SGLT-2 (sodium-glucose cotransporter-2) inhibitors includes, among other things, cardiorenal protection in patients with non-diabetic chronic kidney disease (CKD), as impressively demonstrated by large RCTs in adults (e.g., DAPA-CKD, EMPA-KIDNEY) have impressively demonstrated. Meanwhile, a Phase III study called DOUBLE PROTECT Alport (NCT05944016) has been launched to investigate the efficacy and safety of SGLT2 inhibitors as an add-on to standard therapy in patients aged 10\u201340 with genetic CKD (Alport syndrome).<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fthe-sglt-2-inhibitor-dapagliflozin-as-an-add-on-to-ras-blockade%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>The broad spectrum of therapeutic effects of SGLT-2 (sodium-glucose cotransporter-2) inhibitors includes, among other things, cardiorenal protection in patients with non-diabetic chronic kidney disease (CKD), as impressively demonstrated by large&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fthe-sglt-2-inhibitor-dapagliflozin-as-an-add-on-to-ras-blockade%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":565827,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Genetic Kidney Disease: DOUBLE PROTECT Alport","footnotes":"[{\"content\":\"<em>estimated glomerular filtration rate (eGFR) >60 mL\\\/min\\\/1.73 m\\u00b2;<\\\/em>\",\"id\":\"de281f80-e833-44d8-8f97-4476b5bc7e6c\"},{\"content\":\"<em>With regard to canagliflozin, which is also an SGLT-2 inhibitor, Swissmedic\\u2019s approval is currently limited to diabetic nephropathy in adults (as of September 3, 2026).<\\\/em>\",\"id\":\"6d28f7e2-6362-4781-bb54-2555ce6ea639\"}]","_members_access_role":[],"_members_access_error":""},"category":[11548,11508,11297,11396,11413,11503],"tags":[23472,100904,71810,12821,66543,23427,100900,100901,21430,100903,100902,24162],"powerkit_post_featured":[],"class_list":["post-565826","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-general-internal-medicine","category-genetics","category-nephrology","category-studies","tag-add-on-en","tag-adjunctive-therapy","tag-cardiorenal-protection","tag-ckd-en","tag-dapa-ckd-en","tag-dapagliflozin-en","tag-double-protect-alport","tag-genetic-ckd","tag-kidney-disease","tag-nct05944016","tag-ras-blockade","tag-sglt-2-inhibitor-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-05 02:35:03","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":565832,"slug":"la-dapagliflozine-un-inhibiteur-du-sglt-2-en-traitement-dappoint-a-un-inhibiteur-du-sra","post_title":"La dapagliflozine, un inhibiteur du SGLT-2, en traitement d'appoint \u00e0 un inhibiteur du SRA","href":"https:\/\/medizinonline.com\/fr\/la-dapagliflozine-un-inhibiteur-du-sglt-2-en-traitement-dappoint-a-un-inhibiteur-du-sra\/"},"it_IT":{"locale":"it_IT","id":565836,"slug":"linibitore-sglt-2-dapagliflozina-come-terapia-aggiuntiva-alla-terapia-con-inibitori-del-sistema-renina-angiotensina-ras","post_title":"L'inibitore SGLT-2 dapagliflozina come terapia aggiuntiva alla terapia con inibitori del sistema renina-angiotensina (RAS)","href":"https:\/\/medizinonline.com\/it\/linibitore-sglt-2-dapagliflozina-come-terapia-aggiuntiva-alla-terapia-con-inibitori-del-sistema-renina-angiotensina-ras\/"},"pt_PT":{"locale":"pt_PT","id":565842,"slug":"o-inibidor-da-sglt-2-dapagliflozina-como-tratamento-complementar-a-inibicao-do-sra","post_title":"O inibidor da SGLT-2 dapagliflozina como tratamento complementar \u00e0 inibi\u00e7\u00e3o do SRA","href":"https:\/\/medizinonline.com\/pt-pt\/o-inibidor-da-sglt-2-dapagliflozina-como-tratamento-complementar-a-inibicao-do-sra\/"},"es_ES":{"locale":"es_ES","id":565847,"slug":"la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra","post_title":"La dapagliflozina, un inhibidor de la SGLT-2, como tratamiento complementario al bloqueo del SRA","href":"https:\/\/medizinonline.com\/es\/la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/565826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=565826"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/565826\/revisions"}],"predecessor-version":[{"id":568598,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/565826\/revisions\/568598"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/565827"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=565826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=565826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=565826"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=565826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}